Total number of participants | 23* |
Age (years) | 60.7 (10.4) |
Men/women | 16/7 |
Smokers | 3 |
NYHA class II/III | 14/9 |
LVEF (%) | 30.1 (7.7) |
Time from first diagnosis (months) | 46.7 (54.6) |
Normal coronary angiogram | 15† |
Abnormal coronary angiogram | 4§ |
Type 2 diabetes | 4 |
Hypertension | 8 |
Body mass index (kg/m2) | 27.2 (4.9) |
Systolic blood pressure (mm Hg) | 120.8 (16.5) |
Diastolic blood pressure (mm Hg) | 77.8 (8.9) |
MAP (mm Hg) | 92.1 (11.1) |
Serum urea (mmol/l) | 7.5 (3.0) |
Serum creatinine (µmol/l) | 0.09 (0.02) |
Plasma glucose (mmol/l) | 5.5 (2.5) |
Serum GGT (mmol/l) | 47.9 (63.3) |
Serum AST (mmol/l) | 23.5 (7.4) |
hsCRP (mg/l) | 2.02 (0.33) |
Fibrinogen (g/l) | 3.3 (0.1) |
UACR (g/mol) | 0.95 (0.12) |
Concomitant drugs | |
Furosemide | 18 |
Furosemide dose (mg/day) | 142.2 (341.5) |
Enalapril or equivalent | 18 |
Enalapril dose (mg/day) | 13.9 (7.4) |
ATIIRB | 4 |
β blocker | 13 |
Digitalis | 2 |
Spironolactone | 4 |
Aspirin | 14 |
Aspirin dose (mg/day) | 167.9 (75.0) |